Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 616 AL 630

Microglia: biology and pathology

Graeber MB, Streit WJ.

Acta Neuropathol. 2010 Jan;119(1):89-105. doi: 10.1007/s00401-009-0622-0. Epub 2009 Dec 13.

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study

Eggert K, Skogar O, Amar K, Luotonen L, Kuoppamäki M, Leinonen M, Nissinen H, Oertel W.

J Neural Transm (Vienna). 2010 Mar;117(3):333-42. doi: 10.1007/s00702-009-0344-4. Epub 2009 Dec 15.

External validation of abbreviated versions of the activities-specific balance confidence scale in Parkinson's disease

Lohnes CA, Earhart GM.

Mov Disord. 2010 Mar 15;25(4):485-9. doi: 10.1002/mds.22924.

NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease

Varanese S, Howard J, Di Rocco A.

Mov Disord. 2010 Mar 15;25(4):508-10. doi: 10.1002/mds.22917.

Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease

Cubo E, Martín PM, Martin-Gonzalez JA, Rodríguez-Blázquez C, Kulisevsky J; ELEP Group Members.

Mov Disord. 2010 Jan 15;25(1):70-5. doi: 10.1002/mds.22896.

Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial)

Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K.

Mov Disord. 2010 Jan 15;25(1):97-107. doi: 10.1002/mds.22732.

Novel anti-inflammatory and neuroprotective agents for Parkinson's disease

Lu L, Li F, Wang X.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):232-40. doi: 10.2174/187152710791012035.

A novel parkin-mediated transcriptional function links p53 to familial Parkinson's disease

da Costa CA, Checler F.

Cell Cycle. 2010 Jan 1;9(1):16-7. doi: 10.4161/cc.9.1.10420. Epub 2010 Jan 23.

Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials

Boldyrev AA, Stvolinsky SL, Fedorova TN, Suslina ZA.

Rejuvenation Res. 2010 Apr-Jun;13(2-3):156-8. doi: 10.1089/rej.2009.0923.

Dopaminergic medication boosts action-effect binding in Parkinson's disease

Moore JW, Schneider SA, Schwingenschuh P, Moretto G, Bhatia KP, Haggard P.

Neuropsychologia. 2010 Mar;48(4):1125-32. doi: 10.1016/j.neuropsychologia.2009.12.014. Epub 2009 Dec 16.

Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists

Luthra PM, Mishra CB, Jha PK, Barodia SK.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1214-8. doi: 10.1016/j.bmcl.2009.11.133. Epub 2009 Dec 4.

Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease

Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ, Jeon BS.

Parkinsonism Relat Disord. 2010 Mar;16(3):202-7. doi: 10.1016/j.parkreldis.2009.12.002. Epub 2009 Dec 16.

Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease

Kwak Y, Müller ML, Bohnen NI, Dayalu P, Seidler RD.

J Neurophysiol. 2010 Feb;103(2):942-9. doi: 10.1152/jn.00197.2009. Epub 2009 Dec 16.

The role of DAT-SPECT in movement disorders

Kägi G, Bhatia KP, Tolosa E.

J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):5-12. doi: 10.1136/jnnp.2008.157370.

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia

Darreh-Shori T, Jelic V.

Expert Opin Drug Saf. 2010 Jan;9(1):167-76. doi: 10.1517/14740330903439717.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias